Top-News

Protalix BioTherapeutics Aktie News

Aktie
WKN:  A2PWSL ISIN:  US74365A3095 US-Symbol:  PLX Branche:  Biotechnologie Land:  USA
1,49 €
+0,00 €
0,00%
10:19:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
117,84 Mio. €
Streubesitz
74,58%
KGV
47
Index-Zuordnung
-

Protalix BioTherapeutics News

13.11.25 - PR Newswire
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results PR Newswire
06.11.25 - PR Newswire
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 PR Newswire
28.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
23.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX PR Newswire
02.09.25 - PR Newswire
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
14.08.25 - PR Newswire
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results PR Newswire
07.08.25 - PR Newswire
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 PR Newswire
21.07.25 - PR Newswire
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer PR Newswire
30.06.25 - PR Newswire
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes® PR Newswire
14.05.25 - PR Newswire
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC PR Newswire
09.05.25 - PR Newswire
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results PR Newswire
05.05.25 - PR Newswire
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 PR Newswire
24.03.25 - PR Newswire
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 PR Newswire
17.03.25 - PR Newswire
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results PR Newswire
10.03.25 - PR Newswire
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 PR Newswire
04.02.25 - PR Newswire
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference PR Newswire
23.12.24 - PR Newswire
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Protalix BioTherapeutics Issues 2025 Letter to Stockholders PR Newswire
09.12.24 - PR Newswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »